RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma
International Journal of Molecular Sciences · 26.04.2023 · 24 (9) · 7905
DOI: 10.3390/ijms24097905 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.04.2023. Verfasst von Mingang Pan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, Chongqing 400016, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Research Program of Chongqing Education Commission, Natural Science Foundation Project of Chongqing.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC), the major type of liver cancer, causes a high annual mortality worldwide. RAD51 is the critical recombinase responsible for homologous recombination (HR) repair in DNA damage. In this study, we identified that RAD51 was upregulated in HCC and that RAD51 silencing or inhibition reduced the proliferation, migration, and invasion of HCC cells and enhanced cell apoptosis and DNA damage. HCC cells with the combinatorial treatments of RAD51 siRNA or inhibitor and sorafenib demonstrated a synergistic effect in inhibiting HCC cell proliferation, migration, and invasion, as well as inducing cell apoptosis and DNA damage. Single RAD51 silencing or sorafenib reduced RAD51 protein expression and weakened HR efficiency, and their combination almost eliminated RAD51 protein expression and inhibited HR efficiency further. An in vivo tumor model confirmed the RAD51 inhibitor’s antitumor activity and synergistic antitumor activity with sorafenib in HCC. RNA-Seq and gene set enrichment analysis (GSEA) in RAD51-inactivated Huh7 cells indicated that RAD51 knockdown upregulated cell apoptosis and G1/S DNA damage checkpoint pathways while downregulating mitotic spindle and homologous recombination pathways. Our findings suggest that RAD51 inhibition exhibits antitumor activities in HCC and synergizes with sorafenib. Targeting RAD51 may provide a novel therapeutic approach in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, Chongqing 400016, China.
- The First Clinical Medical Institute, Henan University of Chinese Medicine, Zhengzhou 450000, China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
ORCID-Profile: Jie Xia
Förderung
- Science and Technology Research Program of Chongqing Education Commission
- Natural Science Foundation Project of Chongqing
Zitieren
APA
Pan, M., Sha, Y., Qiu, J., Chen, Y., Liu, L., Luo, M., Huang, A., & Xia, J. (2023). RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 24(9), 7905. https://doi.org/10.3390/ijms24097905
Vancouver
Pan M, Sha Y, Qiu J, Chen Y, Liu L, Luo M, et al. RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023;24(9):7905. doi:10.3390/ijms24097905
BibTeX
@article{Pan2023,
author = {Pan, Mingang and Sha, Yu and Qiu, Jianguo and Chen, Yunmeng and Liu, Lele and Luo, Muyu and Huang, Ailong and Xia, Jie},
title = {RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {9},
pages = {7905},
doi = {10.3390/ijms24097905}
}
EUVIMED